The MarketReader Minute
đź’ŠEmergent BioSolutions Surges on WHO's Mpox Emergency Alert, While BioNTech Slips After Vaccine Trial Setback | Biotech Sector Insights
BioNTech's stock price fell following the announcement of mixed results from its Phase 3 clinical trial of a combined mRNA vaccine for influenza and COVID-19, which showed strong efficacy against influenza A and SARS-CoV-2 but inadequate immunity against influenza B.